Today: 27 January 2026
Subscribe
Browse Category

Investment Analysis News 17 October 2025 - 19 October 2025

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

What to Know Before Markets Open on October 20, 2025 VKTX Stock Steadies After Volatile Stretch Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53 Marketbeat, roughly flat on the week and not far from its intraday high of ~$36.80 on Thursday Vikingtherapeutics. This marks a dramatic recovery…
19 October 2025
···
Ford Stock Plunges Amid $1B Supplier Fire, EV Slump & Record Recalls – What’s Next?

Ford Stock Plunges Amid $1B Supplier Fire, EV Slump & Record Recalls – What’s Next?

Stock Performance in Recent Days Ford’s shares have been on a roller-coaster. After rallying near 52-week highs (around $12.00+ in late summer), the stock tumbled in early October on a cascade of bad news. As of the Oct. 17 close, Ford stock was about $11.92 ts2.tech. Analysts note the stock remains roughly 20–30% higher YTD ts2.tech, but volatility spiked after…
19 October 2025
····
Navitas (NVTS) Stock Skyrockets on NVIDIA AI Chip News — Record Rally Sparks Bull-Bear Debate

Navitas (NVTS) Stock Skyrockets on NVIDIA AI Chip News — Record Rally Sparks Bull-Bear Debate

NVTS Stock Rally and Recent Performance Navitas’s stock has exploded higher in mid-October. On Oct. 13 (Monday), NVTS jumped ~17–21% intraday after markets when the company announced new GaN/SiC power devices for NVIDIA’s next-gen data centers ts2.tech Finviz. The rally accelerated each day: by Oct. 16 NVTS closed at $15.63, its highest ever, following five straight gains ts2.tech ts2.tech. Overall,…
19 October 2025
····
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in…
19 October 2025
···
NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

Nvidia’s $4 Trillion AI Frenzy: NVDA Stock Flirts with Record Highs Amid New Risks, Analysts See More Upside

NVDA Stock Rollercoaster Near Record Highs Nvidia’s stock (NASDAQ: NVDA) has been on a wild ride this month. Shares reached an all-time high around $195.62 in early October amid frenzied buying, only to reverse sharply a few days later ts2.tech. By Oct. 14, NVDA plunged over 4% in one session to roughly $180 as traders took profits and a broader…
18 October 2025
····
New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

New Era Energy (NUAI) Stock Skyrockets on AI Data Center Pivot – Can the Rally Last?

Key Stock Metrics: Metric Value (as of Oct 17, 2025) Closing Price $4.55 Investing 1-Day Change +44.4% (vs $3.15 prev. close) Stockanalysis Day’s Range $3.20 – $4.71 Stockanalysis Volume (Oct 17) 33.82 million Stockanalysis Market Cap ~$129.3 million Investing 52-Week Range $0.32 – $12.29 Stockanalysis AI Data Center Pivot Fuels Wild Rally New Era’s stock has rocketed in October thanks…
18 October 2025
····
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Stock Price and Performance As of mid-October 2025, Sellas Life Sciences (NASDAQ:SLS) trades around $2.10–2.20. This is near the top of its 52-week range ($0.77 low) and about twice its price at the start of 2025 Stockanalysis Marketbeat. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity (761% above average)…
18 October 2025
···
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics, a clinical-stage biotech developing the RaniPill® capsule for oral delivery of biologic drugs, was essentially flat around $0.45–$0.50 from mid-September through early October. On Oct. 17, it announced a collaboration with Chugai (which is majority-owned by Roche Reuters) to turn one of Chugai’s injectable rare-disease antibodies into a pill formulation. The news, coupled with the new funding, ignited…
18 October 2025
···
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Key Facts – October 18, 2025 GILD Stock Price Rallies to New Heights Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81 Stockanalysis Stockanalysis. That rally marked a new 2025 high for the biotech…
18 October 2025
····
IBM Stock Soars on Quantum Breakthrough and AI Revival – Key Updates (Sept 25, 2025)

IBM Stock Hits Multi-Year High on AI & Quantum Hype – Can the Rally Last?

IBM’s Big 2025 Rally Powered by AI Ambitions International Business Machines (NYSE: IBM) has staged a remarkable comeback in 2025. After languishing for much of the past decade, IBM’s stock has roared back to life, reaching levels not seen in years. It briefly hit an intraday high of ~$296 in late September when news of a quantum computing feat with…
17 October 2025
····
Oscar Health Stock Skyrockets on AI-Fuelled Growth Plans – Analysts Warn of ACA Risks

Oscar Health Stock Skyrockets on AI-Fuelled Growth Plans – Analysts Warn of ACA Risks

Key Facts: – Oscar Health (NYSE: OSCR) shares have surged in early October 2025, recently trading around $21–22 (up ~40% YTD) ts2.tech Marketbeat. The stock hit about $21.50 on Oct 3 (+11% on the day) and was trading near $21.76 on Oct 14 (+6.7%) ts2.tech Marketbeat. – Oscar announced a $410 million convertible debt offering in September 2025 to fund…
17 October 2025
···
1 … 248 249 250 251 252 … 257

Stock Market Today

  • KLA Corp's Stock Valuation Questioned After 121% Surge Amid Strong Market Performance
    January 26, 2026, 9:53 PM EST. KLA Corp (KLAC) has surged 121.5% over the past year, closing recently at $1,543.03 despite a 1.6% weekly decline. Despite its strong returns and semiconductor sector role, valuation checks flag concerns. Simply Wall St's discounted cash flow (DCF) model, which discounts future projected cash flows to present value, estimates an intrinsic value of $619.73 per share, suggesting the stock is overvalued by 149%. Additionally, KLA's price-to-earnings (P/E) ratio stands at 47.9 times, aligning broadly with sector peers but reflecting high growth expectations. Investors are advised to weigh these valuation metrics carefully alongside past performance before considering new positions in KLA.
Go toTop